|
|
Blood, 1 August 2008, Vol. 112, No. 3, pp. 848-855.
Prepublished online as a Blood First Edition Paper on May 14, 2008; DOI 10.1182/blood-2007-11-122598.
 Previous Article | Next Article 
Submitted November 7, 2007
Accepted March 18, 2008
Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets
Maria Dona, Gabrielle Fredman, Jan M. Schwab, Nan Chiang, Makoto Arita, Ahmad Goodarzi, Guiying Cheng, Ulrich H. von Andrian, and Charles N. Serhan*
CET&RI, Dept. Anesthesiology, Perioperative and Pain Medicine, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, United States
Department of Pathology, Harvard Medical School, Boston, MA, United States
* Corresponding author; email: cnserhan{at}zeus.bwh.harvard.edu.
Resolvin E1 (RvE1) is an omega-3 eicosapentaenoic acid (EPA)-derived lipid mediator generated during resolution of inflammation and in human vasculature via leukocyte-endothelial cell interactions. RvE1 possesses anti-inflammatory and pro-resolving actions. Here, we report that RvE1 in human whole blood rapidly regulates leukocyte expression of adhesion molecules. RvE1 in the 10-100 nM range stimulated L-selectin shedding, while reducing CD18 expression in both neutrophils and monocytes. When added to whole blood, RvE1 did not stimulate reactive oxygen species by either neutrophils or monocytes, nor did it directly stimulate cytokine/chemokine production in heparinized blood. Intravital microscopy (IVM) demonstrated that RvE1 rapidly reduced leukocyte rolling (~40%) in venules of mice. In human platelet-rich plasma (PRP), RvE1 selectively blocked both ADP-stimulated and thromboxane receptor agonist U46619-stimulated platelet aggregation in a concentration-dependent manner. In contrast,  6,14-trans-RvE1 isomer was inactive. RvE1 did not block collagen-stimulated aggregation, and regulation of ADP-induced platelet aggregation was not further enhanced with aspirin treatment. These results indicate RvE1 is a potent modulator of leukocytes as well as selective platelet responses in blood and PRP, respectively. Moreover, they demonstrate novel agonist-specific anti-platelet actions of RvE1 that are potent and may underlie some of the beneficial actions of EPA in humans.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
| |
